LTR Pharma Ltd Total Liabilities
LTR Pharma Ltd total liabilities. Based on the latest financial reports, LTR Pharma Ltd (LTP) has total liabilities worth AU$457.81K AUD (≈ $323.93K USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See LTR Pharma Ltd (LTP) liquidity interval to measure how many days the company can operate on defensive assets alone.
Total Liabilities of LTR Pharma Ltd (2021–2025)
Total liabilities of LTR Pharma Ltd from 2021 to 2025. This chart illustrates how LTR Pharma Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore investment intensity of LTR Pharma Ltd to see how much of total assets are deployed in long-term investments.
LTR Pharma Ltd Competitors by Total Liabilities
The table below lists competitors of LTR Pharma Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Conexeu Sciences Inc. Common Stock
NASDAQ:CNXU
|
USA | $1.00 Million |
|
Duran-Dogan Basim ve Ambalaj Sanayi AS
IS:DURDO
|
Turkey | TL1.36 Billion |
|
Aztek Teknoloji Urunleri Ticaret A.S.
IS:AZTEK
|
Turkey | TL2.90 Billion |
|
Arrienda Rental Properties SOCIMI SA
MC:YARP
|
Spain | €23.66 Million |
|
ZenaTech Inc.
NASDAQ:ZENA
|
USA | $26.31 Million |
|
Evermore Chemical Industry Co Ltd
TW:1735
|
Taiwan | NT$1.56 Billion |
|
DP POLAND PLC
F:2OP
|
Germany | €19.33 Million |
|
Optex Systems Holdings, Inc. Common Stock
NASDAQ:OPXS
|
USA | $4.74 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down LTR Pharma Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is LTR Pharma Ltd's balance sheet.
Liquidity & Leverage Metrics
LTR Pharma Ltd Total Liabilities Ratios Explained
LTR Pharma Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 57.47 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.02 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.02 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how LTR Pharma Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for LTR Pharma Ltd (2021–2025)
The table below shows the annual total liabilities of LTR Pharma Ltd from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$700.57K ≈ $495.70K |
+63.48% |
| 2024-06-30 | AU$428.54K ≈ $303.22K |
+1915.71% |
| 2023-06-30 | AU$21.26K ≈ $15.04K |
-95.53% |
| 2022-06-30 | AU$475.91K ≈ $336.74K |
+2.68% |
| 2021-06-30 | AU$463.50K ≈ $327.96K |
-- |
About LTR Pharma Ltd
LTR Pharma Limited, a clinical-stage pharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia. Its lead product candidate is SPONTAN, an intranasal delivery technology, an oral PDE5 inhibitor and vardenafil HCL for the treatment of ED. The company was incorporated in 2020 and is headquartered in Brisbane, Australi… Read more